WallStreetZenWallStreetZen

NASDAQ: SBFM
Sunshine Biopharma Inc Stock Ownership - Who owns Sunshine Biopharma?

Insider buying vs selling

Have Sunshine Biopharma Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Steve N. SlilatyChief Executive Officer2024-03-04100,000$0.10
$10.00kBuy
Steve N. SlilatyChief Executive Officer2024-02-0820,000$0.10
$2.00kBuy

1 of 1

SBFM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SBFM insiders and whales buy or sell their stock.

SBFM Shareholders

What type of owners hold Sunshine Biopharma Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Renaissance Technologies LLC24.34%4,610,900$1.40MInstitution
Malek Chamoun19.53%3,700,000$1.12MInsider
Citadel Advisors LLC2.91%550,514$166.81kInstitution
Bridgeway Capital Management LLC1.51%286,100$86.69kInstitution
Camille Sebaaly0.92%174,465$52.86kInsider
Steve N. Slilaty0.69%130,000$39.39kInsider
Jane Street Group LLC0.46%87,610$26.55kInstitution
Royal Bank Of Canada0.34%65,000$19.70kInstitution
Xtx Topco Ltd0.28%53,722$16.28kInstitution
Geode Capital Management LLC0.11%20,179$6.11kInstitution

1 of 3

SBFM vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SBFM30.20%21.14%Net Buying
HUGE1.64%0.00%
UPC0.04%0.00%
SHPH0.39%59.49%Net Selling
IMCC8.04%0.00%

Sunshine Biopharma Stock Ownership FAQ

Who owns Sunshine Biopharma?

Sunshine Biopharma (NASDAQ: SBFM) is owned by 30.20% institutional shareholders, 21.14% Sunshine Biopharma insiders, and 48.66% retail investors. Malek Chamoun is the largest individual Sunshine Biopharma shareholder, owning 3.70M shares representing 19.53% of the company. Malek Chamoun's Sunshine Biopharma shares are currently valued at $1.45M.

If you're new to stock investing, here's how to buy Sunshine Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.